| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/12/2006 | EP1679063A1 Novel liquid preparation composition |
| 07/12/2006 | EP1679059A2 Utilization of vinpocetine to avoid complications in particular those associated to hearing which occur with epilepsy, and treatment thereof |
| 07/12/2006 | EP1679058A1 Pharmaceutical composition for the treatment of angiocardiopathy |
| 07/12/2006 | EP1678499A2 Chemical compound and assay |
| 07/12/2006 | EP1678322A2 Methods and compositions for identifying therapeutic compounds |
| 07/12/2006 | EP1678321A1 Methods and compositions for identifying therapeutic compounds |
| 07/12/2006 | EP1678302A1 Antisense oligonucleotides for prevention of metastasis formation of cancer cells |
| 07/12/2006 | EP1678212A1 Hypo- and hyper-acetylated meningococcal capsular saccharides |
| 07/12/2006 | EP1678211A2 Sulfoalkyl ether-alkyl ether cyclodextrin derivatives |
| 07/12/2006 | EP1678202A1 Hcv ns3-ns4a protease resistance mutants |
| 07/12/2006 | EP1678194A1 The moduilation of hyaluronan synthesis and degradation in the treatment of disease |
| 07/12/2006 | EP1678191A1 Method for the direct synthesis of oligorhamnosides, composition comprising oligorhamnosides and use thereof as a medicament |
| 07/12/2006 | EP1678189A2 Process for the preparation of trans- or cis-diammoniumdichlorodihydroxyplatinum(iv) salts and derivatives and their use for the preparation of pharmaceutical active agents |
| 07/12/2006 | EP1678185A1 2,3-dihydro-6-nitroimidazo [2,1-b] oxazole compounds for the treatment of tuberculosis |
| 07/12/2006 | EP1678184A1 3-(4-aminophenyl)thienopyrimid-4-one derivatives as mch r1 antagonists for the treatment of obesity, diabetes, depression and anxiety |
| 07/12/2006 | EP1678183A1 Spirofuropyridine aryl derivatives |
| 07/12/2006 | EP1678181A2 A2b adenosine receptor antagonists |
| 07/12/2006 | EP1678180A1 Substituted 2h- 1,2,4 triazolo 4,3-a pyrazines as gsk-3 inhibitors |
| 07/12/2006 | EP1678175A2 Cftr channel modulators |
| 07/12/2006 | EP1678173A2 4-heterobicyclylamino-substituted quinazolines and analogues thereof as capsaicin-antagonists |
| 07/12/2006 | EP1678172A2 Azabicyclic compounds for relieving pain and treating central nervous system disorders |
| 07/12/2006 | EP1678171A1 Pyrimidin-4-yl-3,4-thione compounds and their use in therapy |
| 07/12/2006 | EP1678167A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases |
| 07/12/2006 | EP1678166A2 Protein kinase inhibitors |
| 07/12/2006 | EP1678165A2 Method for the production of amino crotonyl compounds |
| 07/12/2006 | EP1678163A1 Novel imidazole derivatives and their use as pharmaceutical agents |
| 07/12/2006 | EP1678161A2 Thioether-substituted benzamides as inhibitors of factor xa |
| 07/12/2006 | EP1678160A1 Pyrazine derivatives and pharmaceutical use thereof |
| 07/12/2006 | EP1678156A1 Novel tricyclic spiroderivatives as modulators of chemokine receptor activity |
| 07/12/2006 | EP1678148A1 Process for the preparation of amorphous rosuvastatin calcium |
| 07/12/2006 | EP1678145A2 Benzimidazoles useful as modulators of ion channels |
| 07/12/2006 | EP1678144A1 1,5,7-TRISUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-a RECEPTOR COMPLEX |
| 07/12/2006 | EP1678135A1 Process for the preparation of n-amino substituted heterocyclic compounds |
| 07/12/2006 | EP1678133A1 Sequence selective pyrrole and imidazole polyamide metallocomplexes |
| 07/12/2006 | EP1678130A2 Amidomethyl-substituted 2-(4-sulfonilamino)-3-hidroxy-3,4-dihydro-2h-chromium-6-yl-derivatives and drugs containing said compounds |
| 07/12/2006 | EP1678126A2 Prodrugs of diaryl-2-(5h)-furanone cyclooxygenase-2 inhibitors |
| 07/12/2006 | EP1678124A1 Novel molecules to develop drug for the treatment of osteoporosis |
| 07/12/2006 | EP1678121A2 Tao kinase modulators and methods of use |
| 07/12/2006 | EP1678078A1 Methods and articles for maintaining hydantoinylated polymers in a biocidally active state |
| 07/12/2006 | EP1677827A2 Combinations for hcv treatment |
| 07/12/2006 | EP1677822A2 4'-thionucleosides and oligomeric compounds |
| 07/12/2006 | EP1677812A2 Treating or preventing restless legs syndrome using prodrugs of gaba analogs |
| 07/12/2006 | EP1677808A1 Combined preparation for treating sepsis |
| 07/12/2006 | EP1677807A2 Use of biocompatible polymers for the preparation of a composition or a medical device |
| 07/12/2006 | EP1677806A1 Methods for treating acute and overuse sprain and strain using hyaluronic acid |
| 07/12/2006 | EP1677805A2 Pancreatic cancer treatment |
| 07/12/2006 | EP1677804A1 Silyl phenols for promoting vascular health |
| 07/12/2006 | EP1677803A2 Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers |
| 07/12/2006 | EP1677802A2 1,3 aclyated 24-keto-vitamin d3 compounds and methods of use thereof |
| 07/12/2006 | EP1677801A1 Triterpene compounds which are effective on improvement of brain function |
| 07/12/2006 | EP1677798A2 Once-a-day, oral, controlled-release, oxycodone dosage forms |
| 07/12/2006 | EP1677797A2 Salts and polymorphs of a potent antidiabetic compound |
| 07/12/2006 | EP1677796A2 Muscarinic acetylcholine receptor antagonists field of the invention |
| 07/12/2006 | EP1677795A1 Muscarinic acetycholine receptor antagonists |
| 07/12/2006 | EP1677794A2 Methods of treating disorder |
| 07/12/2006 | EP1677793A1 The use of non-opiates for the potentation of opiates |
| 07/12/2006 | EP1677792A1 Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester |
| 07/12/2006 | EP1677791A2 Nitrogen-containing fused heterocyclic compounds |
| 07/12/2006 | EP1677787A1 Combinations of potassium channel openers and sodium channel inhibitors or active substances influencing sodium channels in order to treat painful conditions |
| 07/12/2006 | EP1677786A1 5-substituted 2-(phenylmethyl)thio-4-phenyl-4h-1,2,4-triazole derivatives and related compounds as gaba-agonists for the treatment of urinary incontinence and related diseases |
| 07/12/2006 | EP1677785A1 Benzimidazole derivatives and use thereof as peptide deformylase inhibitors |
| 07/12/2006 | EP1677784A1 Indole antiviral compositions and methods |
| 07/12/2006 | EP1677782A2 Inhibitors of cathepsin s |
| 07/12/2006 | EP1677781A1 Salts of pharmacologically active compounds |
| 07/12/2006 | EP1677780A2 Dietary and other compositions, compounds, and methods for reducing body fat, controlling appetite, and modulating fatty acid metabolism |
| 07/12/2006 | EP1677779A1 Novel association consisting of an anti-atherothrombotic agent and of a platelet antiaggregating agent |
| 07/12/2006 | EP1677778A2 Method of treating airway diseases with beta-adrenergic inverse agonists |
| 07/12/2006 | EP1677777A1 Pellets containing venlafaxine hydrochloride |
| 07/12/2006 | EP1677776A1 Extended release tablet formulations of venlafaxine |
| 07/12/2006 | EP1677775A2 Therapeutic use of methionine for the treatment or prevention of mucositis |
| 07/12/2006 | EP1677774A1 Citicoline-based composition in combination with vitamins for the prevention and treatment of eye pathologies |
| 07/12/2006 | EP1677773A1 Combination therapy for cancer |
| 07/12/2006 | EP1677772A1 Oral antidepressant formulation comprising acetylsalicylic acid to accelerate onset of action |
| 07/12/2006 | EP1677771A2 Transdermal analgesic systems having reduced abuse potential |
| 07/12/2006 | EP1677770A2 Stable lansoprazole formulation |
| 07/12/2006 | EP1677769A1 Controlled release formulations exhibiting an ascending rate of release |
| 07/12/2006 | EP1677768A2 Extended release formulations of opioids and method of use thereof |
| 07/12/2006 | EP1677767A2 Crystalline form of gamma-aminobutyric acid analog |
| 07/12/2006 | EP1677765A1 Preparation of lipid particles |
| 07/12/2006 | EP1677761A1 Suspension of loteprednol etabonate and tobramycin for topical ophthalmic use |
| 07/12/2006 | EP1677760A2 Controlled release analgesic suspensions |
| 07/12/2006 | EP1677759A1 Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin |
| 07/12/2006 | EP1677758A1 Compositions and dosage forms for enhanced absorption of 3-amino-n-butyl-phosphinic acid |
| 07/12/2006 | EP1677757A2 Compositions and dosage forms for enhanced absorption |
| 07/12/2006 | EP1677756A2 Administration of levodopa and carbidopa |
| 07/12/2006 | EP1677754A1 Methods and compositions for treating erectile dysfunction |
| 07/12/2006 | EP1677745A2 Nitrone compounds prodrugs and pharmaceutical compositions of the same to treat human disorders |
| 07/12/2006 | EP1677744A2 Compositions and methods for treatment of muscle pain and muscle wasting |
| 07/12/2006 | EP1677740A2 Methods and compositions for treating cancer |
| 07/12/2006 | EP1677732A2 Disinfecting teat care compositions |
| 07/12/2006 | EP1677731A2 Thiophene and benzothiophene hydroxamic acid derivatives |
| 07/12/2006 | EP1677718A2 Treatment of overuse tendinopathy using transdermal nitric oxide-generating agents |
| 07/12/2006 | EP1677664A2 Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects |
| 07/12/2006 | EP1677627A1 Dietetic preparation with hyaluronate for treatment of osteoporosis |
| 07/12/2006 | EP1605958B1 Compositions of natural products and use thereof |
| 07/12/2006 | EP1575969B1 SUBSTITUTED 9a-N-(N'- 4-(SULFONYL)PHENYL CARBAMOYL) DERIVATIVES OF 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHROMYCIN A AND 5-0-DESOSAMINYL-9-DEOXO-9-DI-HYDRO-9A-AZA-9A-HOMOERITHRONOLIDE A |
| 07/12/2006 | EP1516866B1 Natural compounds and derivatives thereof for the prevention and treatment of cardiovascular, hepatic and renal diseases and for cosmetic applications |
| 07/12/2006 | EP1496865B1 Method for the production of crystals, crystals obtained by said method, and use thereof in pharmaceutical formulations |
| 07/12/2006 | EP1467750B1 Orodispersible pharmaceutical composition comprising perindopril |
| 07/12/2006 | EP1441718B1 Use of carbinols for the treatment of neuropathic dysfunction |